BioMarin Pharmaceutical Inc. buy Guggenheim
Start price
28.02.23
/
50%
€94.17
Target price
28.02.24
€117.80
Performance (%)
-13.41%
End price
29.02.24
€81.54
Summary
This prediction ended on 29.02.24 with a price of €81.54. The prediction for BioMarin Pharmaceutical Inc. disappointed with a performance of -13.41%. Guggenheim has a follow-up prediction for BioMarin Pharmaceutical Inc. where he still thinks BioMarin Pharmaceutical Inc. is a Buy. Guggenheim has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
BioMarin Pharmaceutical Inc. | -7.208% | -7.208% | -9.264% |
iShares Core DAX® | -1.611% | 3.135% | 15.880% |
iShares Nasdaq 100 | -0.500% | 0.775% | 20.054% |
iShares Nikkei 225® | -1.483% | 4.610% | 11.154% |
iShares S&P 500 | -0.501% | 1.914% | 21.016% |
Comments by Guggenheim for this prediction
In the thread BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $125.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
In the thread Trading BioMarin Pharmaceutical Inc.
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten
Current prediction by Guggenheim for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€85.26
13.09.23
13.09.23
€102.48
13.09.24
13.09.24
-9.71%
10.09.24
10.09.24